JPRN-jRCT2031200377招募中未知
ong term special drug use-results surveillance for Mayzent in SPMS patients (prevention of relapses and prevention of physical disability progression in secondary progressive multiple sclerosis , CBAF312A1401)
Sugimoto Toshiya0 个研究点目标入组 330 人开始时间: 2021年3月1日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •All patients using Mayzent for the following indication for a specified post-marketing period of time
- •Indication: prevention of secondary progressive multiple sclerosis recurrences and prevention of physical disability progression
排除标准
- 未提供
研究者
相似试验
招募中
Unknown
Special drug use-results surveillance <Patients with cold agglutinin disease>Cold agglutinin diseaseJPRN-UMIN000049607sanofi K.K.100
招募中
不适用
Special Drug Use Results Surveillance for the use of Odefsey in pregnant womeHIV/AIDSJPRN-UMIN000034028Janssen Pharmaceutical K.K.3
已完成
不适用
Special drug use results surveillance for the use of SIMPONI in ulcerative colitisulcerative colitisJPRN-UMIN000027542Janssen Pharmaceutical K.K.300
已完成
不适用
Special Drug Use-results Surveillance for long term administration in adult (18 years and older) of CONCERTA, 18mg/ 27mg/ 36mg TabletsAttention deficit hyperactivity disorder (ADHD)JPRN-UMIN000015900Janssen Pharmaceutical K.K500
已完成
不适用
Special Drug Use-results Surveillance for long term administration of XEPLION (Paliperidone Palmitate 1 month formulation), 25mg/ 50mg/ 75mg/ 100mg/ 150mg syringeSchizophreniaJPRN-UMIN000018665Janssen Pharmaceutical K.K.1,050